McKinsey's four drug launch flavors: Good, bad, ugly and misguided

What's the probability of a good drug launch? About one in three, according to a new McKinsey & Co. analysis. And if a launch is good, it tends to be very, very good, beating forecasts year after year. That means two-thirds of drug launches fall short of expectations. And once a drug launch goes bad, it stays bad. Fortunately, says McKinsey, a sharp analysis of the product and its market can start things off on the right track. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.